MYCN gene amplification occurs in approximately 25% of patients with neuroblastoma. MYCN gene amplification is associated with infiltration, metastasis and poor prognosis of neuroblastoma. When the MYCN gene amplification factor is less than 10, the clinical treatment plan may not be treated after the complete removal of the primary tumor; when the MYCN gene amplification factor is >10, the conventional chemotherapy should be performed for 12 months after the surgical resection, and local radiotherapy is needed if necessary.